Onconetix's Swiss subsidiary Proteomedix AG reported Q1 2026 progress for Proclarix®, a blood test aiding early detection of significant prostate cancer. Two new peer-reviewed studies confirmed Proclarix's effectiveness in reducing unnecessary biopsies and predicting disease progression. The company also launched the PRIME multi-center validation study in the U.S. with Labcorp, enrolling the first participants to test Proclarix across diverse populations. Meanwhile, European commercial expansion continues with new partnerships and real-world screening initiatives in the UK and Turkey.
SAPHNELO (Anifrolumab), a monoclonal antibody for moderate-to-severe systemic lupus erythematosus (SLE), demonstrates robust clinical efficacy by targeting type I interferon receptors. Approved in over 70 countries, it generated $483 million in sales...
California Governor Gavin Newsom proposed a new tax extending state sales tax to digital prewritten software purchases, aiming to level the playing field between online and physical store sales. The tax, set to take effect January 1, 2027 pending leg...
OCREVUS, a treatment for multiple sclerosis (MS), showed strong sales growth of 9% in 2025, reaching about $7.6 billion globally. Its broad efficacy in treating both relapsing and progressive MS, along with the recent approval of a convenient subcuta...
New York Governor Kathy Hochul proposes a two-phase tax increase on luxury second homes in NYC to address the city's budget deficit. Initially, homes with at least $1 million assessed value will face a 4-6.5% surcharge, potentially translating to pro...
During a state visit to China, President Donald Trump pushed for broader access for U.S. credit card companies like Visa to enter China's financial market. Trump highlighted Visa's exclusion and expressed hope that restrictions might be lifted. This ...
